Publications by authors named "M Scherf-Clavel"
Background: Geriatric depression is challenging to treat owing to age-related changes in pharmacokinetics and comorbidities. Although renal insufficiency and multimorbidity are typical geriatric complications that cannot be completely separated from each other, no study has examined the influence of these factors on the serum concentrations of antidepressants. For the first time, we evaluated the effects of these factors in combination on the dose-corrected serum concentration (C/D) of antidepressants in geriatric patients.
View Article and Find Full Text PDFTherapeutic drug monitoring in children and adolescents with schizophrenia-spectrum, affective, behavioural, tic and other psychiatric disorders treated with aripiprazole: results of the TDM-VIGIL pharmacovigilance study.
J Neural Transm (Vienna)
November 2024
Article Synopsis
- Aripiprazole, a medication approved for severe mental disorders, is often prescribed off-label to children and adolescents, yet there are no established therapeutic serum level reference ranges for this population.
- A study aimed to investigate the relationship between aripiprazole dosage and serum concentrations in youth, identifying factors like sex, age, and weight that might influence these levels.
- The findings suggested a strong correlation between daily dosage and serum concentration, leading to a preliminary reference range for treating pediatric patients, which indicated potentially better outcomes and fewer side effects when using interquartile ranges for dose determination.
Introduction: Fluvoxamine is used in children and adolescents ('youths') for treating obsessive compulsive disorder (OCD) but also off-label for depressive and anxiety disorders. This study aimed to investigate the relationship between fluvoxamine dose and serum concentrations, independent correlates of fluvoxamine concentrations, and a preliminary therapeutic reference range (TRR) for youths with OCD and treatment response.
Methods: Multicenter naturalistic data of a therapeutic drug monitoring service, as well as prospective data of the 'TDM Vigil study' (EudraCT 2013-004881-33), were analyzed.
Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: Focus on antipsychotics.
World J Biol Psychiatry
November 2024
Background: For psychotic disorders (i.e. schizophrenia), pharmacotherapy plays a key role in controlling acute and long-term symptoms.
View Article and Find Full Text PDFBackground: Approximately 15-25% of depressed patients suffer from difficult-to-treat depression (DTD). Patients with DTD require a thorough examination to avoid the oversight of treatable (psychiatric/somatic) comorbidities or (pseudo-)resistance to antidepressant drugs (ADs). Polymorphisms of the cytochrome P450 (CYP) enzymes 2D6 and 2C19, which play a major role in the metabolism of ADs, may contribute to resistance to ADs.
View Article and Find Full Text PDF